Barrier Seeks Development Partner For Its Liarozole Treatment In Lamellar Ichthyosis
This article was originally published in The Pink Sheet Daily
Phase II/III trial fails to meet primary endpoint; FDA and EMEA want more clinical trials, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Barrier also moving forward with Phase IV commitments, exec tells “The Pink Sheet” DAILY.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.